Pherecydes Pharma reports successful patient treatment with bacteriophages
Phage therapy could offer an alternative treatment method in the fight against antimicrobial resistance
Romainville, France, January 30, 2019 – Pherecydes Pharma, a biotechnology company specialized in the research and development of anti-infective therapies based on the use of bacteriophages, announces that its bacteriophage therapies have been successfully used to treat a patient with relapsing Staphylococcus aureus prosthetic-joint infection (PJI).
Full PR available here